Eli Lilly and Company is named among the 13 Best Long Term Low Risk Stocks to Buy Now. Goldman Sachs raised its price target for Eli Lilly to $1,260, citing a 25% growth outlook. The company reported earnings of $7.54 per share in the fourth quarter, exceeding expectations.

Lilly expects to launch orforglipron, an oral obesity pill, in the U.S. in the second quarter. The company forecasts earnings of $33.50 to $35 per share for 2026, with revenue expected to reach $80 billion to $83 billion. This outlook is well above analyst expectations.

The competitive landscape in the pharmaceutical industry is shifting, with Lilly’s positive growth outlook contrasting with rival Novo Nordisk’s decline in sales forecast. Lilly remains confident in the obesity drug market and expects strong demand for its treatments in 2026.

Eli Lilly and Company is a global pharmaceutical company developing medicines and radiopharmaceutical research for cancer treatment. While LLY is seen as a strong investment, some believe that other AI stocks may offer higher returns with limited downside risk.

For more promising AI stock options with potential upside, investors are encouraged to explore reports on other companies beyond Eli Lilly and Company.

Read more at Yahoo Finance: Goldman Sachs Reaffirms Buy on Eli Lilly and Company (LLY), Citing 25% Growth Outlook